Phase III randomized, multicenter open label study to evaluate the efficacy of immunomodulatory therapy in case of psychiatric disorders with proven dysimmunity.
Latest Information Update: 23 Aug 2022
Price :
$35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Psychiatric disorders
- Focus Therapeutic Use
- Acronyms TIM-DEPIST
- 23 Aug 2022 New trial record